Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Braveheart Bio, Inc. (BRVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After G
How this was made
The 30-second read
Why it matters
The disclosed cash position and trial progress reduce financing risk and could improve valuation multiples for the company.
Market read
First‑time disclosure of Q2 results and trial updates provides fresh data for traders evaluating BRVE.
What to watch
Potential dilution from future financing rounds and regulatory timelines for BHB‑1893.
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
The company initiated its Phase 3 LIONHEART-HCM trial, advanced its nHCM program toward a planned Phase 3 start, completed an IPO, and reported cash and cash equivalents expected to fund projected operating expenses and capital expenditure requirements into 2029. The quarter also reflected materially higher R&D and G&A spending and a larger net loss as development activity expanded.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expensesGAAP | $11.1M | – | – |
| In-process research and developmentGAAP | $— | – | – |
| General and administrative expensesGAAP | $4.8M | – | – |
| Total operating expensesGAAP | $15.88M | – | – |
| Loss from operationsGAAP | −$15.88M | – | – |
| Interest incomeGAAP | $889K | – | – |
| Other incomeGAAP | $5K | – | – |
| Total other incomeGAAP | $894K | – | – |
| Net lossGAAP | $15M | – | – |
| Deemed dividends upon issuance of redeemable convertible preferred stockGAAP | $3.6M | – | – |
| Net loss attributable to common stockholdersGAAP | $18.6M | – | – |
| Net loss per share, basic and dilutedGAAP | $2.51 net loss per share, basic and diluted | – | – |
| Weighted-average shares of common stock outstanding, basic and dilutedGAAP | 7,401,783 | – | – |
| Cash and cash equivalentsGAAP | $122.8M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
into 2029 outlook
- NoteExisting cash and cash equivalents, together with the net proceeds from its IPO, will be sufficient to fund projected operating expenses and capital expenditure requirements into 2029.
- NoteOn track to dose the first patient in LIONHEART-HCM this year.
- NoteResults from an interim analysis from LIONHEART-HCM are expected in the second half of 2027.
- NoteNOBLEHEART-HCM, a global Phase 3 trial in nHCM, is expected to initiate in the first half of 2027.
What drove it
- R&D expense increased primarily due to the advancement of BHB-1893, preparation for the planned global Phase 3 program, and higher personnel-related costs.
- G&A expense increased primarily due to increased headcount and costs supporting increased operations, business development, and preparation for operating as a public company.
- LIONHEART-HCM, a Phase 3 trial of BHB-1893 versus metoprolol in adults with symptomatic oHCM, has been initiated.
- The company has an active U.S. IND and expects to initiate NOBLEHEART-HCM, a global Phase 3 trial in nHCM, in the first half of 2027.
- In the Phase 2 nHCM trial, BHB-1893-treated patients were observed to have statistically significant reductions in secondary cardiac-biomarker endpoints and statistically significant, dose-dependent improvements in myocardial relaxation, hemodynamic benefit, and cardiac remodeling compared with placebo-treated patients.
Concerns
- Braveheart Bio reported no revenue and remains a clinical-stage biopharmaceutical company.
- Net loss increased to $15.0 million from $0.4 million as the company advanced BHB-1893 and built its operating infrastructure.
- Net loss attributable to common stockholders included a $3.6 million non-cash deemed dividend upon the April 2026 issuance of Series A preferred stock.
- Clinical development, regulatory approvals, third-party clinical trial and manufacturing dependencies, additional funding needs, intellectual property, personnel, and competition are identified risks.
What to watch
- First-patient dosing in LIONHEART-HCM this year.
- LIONHEART-HCM interim-analysis results expected in the second half of 2027.
- Initiation of the NOBLEHEART-HCM Phase 3 trial in the first half of 2027.
- R&D expense progression as the global Phase 3 programs advance.
- Execution against the stated cash runway into 2029.
Balance sheet and cash flow
- Cash and cash equivalents were $122.8 million as of June 30, 2026, compared to $89.2 million as of December 31, 2025.
- Cash and cash equivalents would have been approximately $527.3 million on an as-adjusted basis, including approximately $404.5 million of aggregate net IPO proceeds.
- Braveheart Bio issued an aggregate of 60,000,000 shares at $1.00 per share for gross proceeds of $60.0 million in the third closing of its Series A preferred stock financing.
- Braveheart Bio issued an aggregate of 24,437,500 shares of common stock at $18.00 per share for gross proceeds of approximately $439.9 million in its August 2026 IPO.
- Total assets were $126,956 (in thousands) as of June 30, 2026, compared to $89,350 (in thousands) as of December 31, 2025.
- Total liabilities were $9,342 (in thousands) as of June 30, 2026, compared to $5,333 (in thousands) as of December 31, 2025.
- Total stockholders’ deficit was $(95,906) (in thousands) as of June 30, 2026, compared to $(65,872) (in thousands) as of December 31, 2025.
- As of September 3, 2026, Braveheart Bio had 90,038,969 shares of common stock outstanding.
Analysis
Braveheart Bio reported a second-quarter net loss of $15.0 million, compared with a net loss of $0.4 million for the same period in 2025. R&D expense was $11.1 million, compared with $0.0 million, reflecting advancement of BHB-1893, preparation for the planned global Phase 3 program, and higher personnel-related costs. G&A expense was $4.8 million, compared with less than $0.1 million, as headcount and costs supporting expanded operations, business development, and public-company readiness increased.
The period was defined by clinical execution rather than commercial operations. The company initiated LIONHEART-HCM, its Phase 3 trial comparing BHB-1893 with metoprolol in adults with symptomatic oHCM. Sites are being activated and patients are screening, with first-patient dosing targeted this year. In nHCM, the company has an active U.S. IND and expects to initiate the NOBLEHEART-HCM global Phase 3 trial in the first half of 2027. The company expects LIONHEART-HCM interim-analysis results in the second half of 2027.
The reported Phase 2 nHCM update described statistically significant reductions in secondary cardiac-biomarker endpoints, as well as statistically significant, dose-dependent improvements in myocardial relaxation, hemodynamic benefit, and cardiac remodeling compared with placebo-treated patients. The release also stated that no patients in intervention cohorts required trial-drug interruption for LVEF reductions. These clinical observations support the company’s decision to move toward the planned nHCM Phase 3 program, while future Phase 3 execution and data remain the central operating milestones.
Liquidity changed materially after the reporting date. Cash and cash equivalents were $122.8 million at June 30, 2026, versus $89.2 million at December 31, 2025. The August IPO generated approximately $404.5 million of net proceeds, which would have brought cash and cash equivalents to approximately $527.3 million on an as-adjusted basis. Management stated that existing cash, cash equivalents, and IPO proceeds are expected to fund projected operating expenses and capital expenditure requirements into 2029.
The $18.6 million net loss attributable to common stockholders exceeded the $15.0 million net loss because of a $3.6 million non-cash deemed dividend associated with the April 2026 Series A preferred stock issuance. The charge increased loss attributable to common stockholders for EPS purposes but did not affect net loss or cash flows. With no revenue reported, the primary financial watchpoints are the pace of Phase 3-related spending, the stated runway, and delivery of the announced clinical milestones.
Management, verbatim
Sites are being activated and patients are screening for our LIONHEART-HCM Phase 3 study in obstructive HCM (“oHCM”), and we are on track to dose the first patient this year.
Travis Murdoch, M.D., Chief Executive Officer and President of Braveheart Bio
We continue to expect results from an interim analysis from LIONHEART-HCM in the second half of 2027.
Travis Murdoch, M.D., Chief Executive Officer and President of Braveheart Bio
In addition, our program in non-obstructive HCM (“nHCM”) is advancing; we now have an active U.S. investigational new drug application (“IND”) and expect to initiate our NOBLEHEART-HCM Phase 3 study in the first half of 2027.
Travis Murdoch, M.D., Chief Executive Officer and President of Braveheart Bio
Not in the filing
stated, not guessed- Total revenue was not reported.
- Revenue by segment was not reported.
- Gross profit and gross margin were not reported.
- Operating income was not reported; the company reported loss from operations.
- Non-GAAP financial measures, including non-GAAP net income or loss and non-GAAP EPS, were not reported.
- Prior-quarter comparisons for operating expenses, loss from operations, net loss, EPS, and other income were not reported.
- Year-over-year and quarter-over-quarter percentage changes were not reported for the financial line items.
- Operating cash flow and free cash flow were not reported.
- Debt was not reported.
- Dividends and share repurchases were not reported.
- Forward revenue, gross-margin, operating-expense, and tax-rate guidance were not reported.
- A prior outlook section was not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Braveheart Bio recently completed an IPO in August 2026, raising ~$440 M, and is advancing its lead candidate BHB‑1893 through Phase 3 trials for obstructive and non‑obstructive hypertrophic cardiomyopathy.
Ticker impact
SEC 8‑K disclosed Braveheart Bio's Q2 2026 financial results, IPO proceeds and Phase 3 trial initiation for BHB‑1893.
Potential modest upside as investors price in stronger balance sheet and trial progress.
New capital and trial updates are material for a clinical‑stage biotech, but no immediate catalyst for a sharp move.
Market effects
Highlights continued investor interest in cardiovascular biotech pipelines.
Supports broader Nasdaq biotech sentiment.
Limited to biotech sector; no macro impact.
Counterpoint
The cash burn and net loss may outweigh trial optimism, suggesting caution.
Key entities
- companyBraveheart Bio, Inc.
Clinical‑stage biotech developing BHB‑1893 for hypertrophic cardiomyopathy.
- partnerHengrui Pharmaceuticals Co., Ltd.
Collaborated on Phase 2 trial results for BHB‑1893.
